ZeroTLR
@ZeroTLR
Followers
2K
Following
4K
Statuses
4K
Critical view of interventional devices & techniques, let’s keep patients first. Tweets are on my own personal opinion and not medical advice.
United States
Joined September 2017
RT @GilbertTangMD: #TRILUMINATE #TEER #TriClip RCT @ACCinTouch #ACC2023 late breaker by @psorajja No diff vs GDMT in ☠️🏩but ⬆️KCCQ ⬇️TR at…
0
51
0
RT @AlkashkariWail: 85y♂️ NSTEMI, 5y ago had TAVI in embolized TAVI during same procedure. Today, PCI to RCA & angiogram to LM done (LAD n…
0
1
0
RT @jgschwartzmd: #CRT2023 @CathElectroSurg on multivariate prediction model for coronary obstruction in native & ViV #TAVR — ✅ measure cu…
0
4
0
RT @mirvatalasnag: #CRT2023 PCI vs CABG for LM dz w & w/out DM 25% DM DM pts more likely to have higher Syntax & co-morbidities PEP: all…
0
14
0
RT @GoldbergJBCTMD: Hypoattenuated Leaflet Thickening (HALT) Operative view of Sapien 3 implanted 6 months prior with #HALT of right and n…
0
32
0
RT @iamritu: @JoaoLCavalcante #CRT23 Bicuspid Anatomy for TAVR The more calcification raphe leaflet LVOT worse mortality Shorter membrano…
0
10
0
RT @DFCapodanno: Current hs-cTn assays are highly valuable for rule-out of AMI. This comes at the price of specificity, unless serial asses…
0
19
0
RT @CathElectroSurg: First-in-human TELLTALE-BASILICA @StFrancis_LI! TELLTALE is the first and only dedicated system for transcatheter elec…
0
49
0
RT @AndreaScotti21: ✨Glad to share at #CRT2023 our @MonteHeart experience on Prophylactic IABP in TF-TAVI 🌐Out now @EuroInterventio: https…
0
19
0
RT @GilbertTangMD: Amazing #ValvePPM app by @bapat_savrtavr @hahn_rt @PPibarot on avoiding PPM and check valve function with ref EOA in AVR…
0
12
0
RT @AkivaRosenzveig: 1/Excited to share our recent @ccijournal publication on the incidence & distribution of missed paravalvular regurgita…
0
18
0
RT @GilbertTangMD: Don’t miss @NytvL today #NewYork Transcatheter Valve. World class speakers, 6 live #TAVR #TEER #TMVR cases! @MountSinaiH…
0
5
0
RT @EuroInterventio: In this multicentre, propensity-matched comparison of the self-expanding ACURATE neo2 and the balloon-expandable SAPIE…
0
11
0
RT @AlkashkariWail: 80y♂️ severe AS heavily ca EF35%, RBBB, LAD prox-mid 90% calcified lesion. PCI to LAD then #TAVR with #evolute_29. Pre&…
0
3
0
RT @GilbertTangMD: Honored to present at #HongKongValves2022 alongside a great lineup of speakers. Hope to go back to my birthplace next ye…
0
3
0
@BaoGTran @CirujaBarbosa @EACTS @JACCJournals @Pooh_Velagapudi @heartsurgeryuk @SusheelKodaliMD “only 51% of patients met all inclusion and exclusion criteria of the PARTNER 3 (The Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low-Risk Patients w Aortic Stenosis) trial (3) & 41% had a clinical variable that was excluded from TAVR v SAVR trials”
0
0
0
RT @AlkashkariWail: 84y♀️ sever AS, perim 62,area 300, SOV 26.6, LM 6.8. #lifetime_management #TAVR @Medtronic #evolute 23mm #cusp_overlap…
0
5
0